ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...

Business remains robust and brokers see ASX stock soaring up to 100%. The post CSL shares look primed to take off — Here's ...

Fintel reports that on December 8, 2025, JEFFERIES maintained coverage of CSL Limited - Depositary Receipt (OTCPK:CSLLY) with a Buy recommendation. As of December 6, 2025, the average one-year price ...

Brokers remain upbeat and see upside up to 95% for the biotech stock. The post CSL shares slide again in March — but is a comeback brewing? appeared first on The Motley Fool Australia.

An announcement from CSL ( (AU:CSL)) is now available. CSL Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program for ordinary fully paid ...

Brokers see significantly more upside ahead for Pro Medicus. The post Forget CSL shares, this ASX healthcare stock could double in value appeared first on The Motley Fool Australia.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or argenex SE (ARGX). But which of these two stocks is more ...

This ASX healthcare giant is out of favour, but that may be where opportunity starts. The post Is it time to get greedy with ...

CSL ( (AU:CSL)) just unveiled an announcement. CSL Limited has reported an update to its ongoing on-market share buy-back program for its ordinary fully paid securities traded on the ASX. The update, ...